Industry Briefs: June 25, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Bristol-Myers Squibb and Pfizer have received a Complete Response Letter from FDA for Eliquis (apixaban), for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Read More
Impax Laboratories and Tolmar have entered into a multiproduct agreement for the development, supply, and distribution of generic topical prescription drug products. Read More
FDA has issued Janssen R&D a Complete Response Letter for Xarelto (rivaroxaban) for the reduction of secondary cardiovascular events in patients with acute coronary syndrome Read More
PharmaNet/i3 has launched PharmaNet/i3 Strategic Resourcing, a new provider of staffing and functional service provider services. Read More
Quotient Clinical and Capsugel have announced a collaboration for the development and clinical assessment of lipid-based formulations. Read More
Takeda North America has changed its name to Takeda Pharmaceuticals USA. Read More
WIL Research Company has selected Thermo Fisher Scientific’s Q Exactive mass spectrometer systems to expand its capabilities for regulated bioanalysis, drug discovery, metabolism, and structural identification services.
People News
Takeda has announced a new assignment of directors, the appointment of corporate officers and a change of senior leadership. Key appointments include Masato Iwasaki as director and senior vice-president of Pharmaceutical Marketing, and Deborah Dunsire as director, president, and CEO of the company’s subsidiary Millennium Pharmaceuticals. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
